Form 4 holding
10%+ Owner
GYRE THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 64,005,887
- Estimated value
- $30,082,767
- Report date
- 30 Oct 2023
- Price
- $0.4700
- Ownership
- See Remarks
GNI Group Ltd.
Insider Reports History
- Reporting-owner location
- Tokyo
- Latest reporting-owner signature
-
/s/ Thomas Eastling, as attorney-in-fact for GNI Group Ltd.
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for GNI Group Ltd.
Form 4 holding
10%+ Owner
GYRE THERAPEUTICS, INC.
- Security class
- Series X Convertible Preferred Stock Warrant (Right to Buy)
- Shares / value
- 8,110,300
- Estimated value
- $1,013,788
- Report date
- 27 Oct 2023
- Price
- $0.1250
- Ownership
- Indirect
- Underlying class
- Series X Convertible Preferred Stock
- Underlying amount
Form 4 holding
10%+ Owner
GYRE THERAPEUTICS, INC.
- Security class
- Series B Preferred Stock
- Shares / value
- 2,143,706
- Estimated value
- Report date
- 04 May 2026
- Price
- Ownership
- See Remarks
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
GYRE THERAPEUTICS, INC.
- Security class
- Series X Convertible Preferred Stock
- Shares / value
- 13,151
- Estimated value
- Report date
- 27 Oct 2023
- Price
- Ownership
- Indirect
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
10%+ Owner
CATALYST BIOSCIENCES, INC.
- Security class
- Series Y Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 31 Aug 2023
- Price
- Ownership
- Direct
Insider Reports Filed by GNI Group Ltd.
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 04 May 2026
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 06 May 2026, 20:40
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 30 Oct 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 22 Nov 2023, 19:27
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 27 Oct 2023
- Transactions
- 2
- Transaction value
- +$4,999,852
- Accepted by SEC
- 31 Oct 2023, 21:56
- Role
- 10%+ Owner
- Next action
- Open filing details
3
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 27 Oct 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 27 Oct 2023, 20:01
- Role
- 10%+ Owner
- Next action
- Open filing details
4
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 31 Aug 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Sep 2023, 16:07
- Role
- 10%+ Owner
- Next action
- Open filing details
3
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 26 Dec 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2023, 15:06
- Role
- 10%+ Owner
- Next action
- Open filing details